Table 2.

Cancer risk in 15,636 patients with primary Sjögren syndrome (list includes only cancer number ≥ 5).

Specific CancerObservedExpectedSIR (95% CI)p
All741521.521.4 (1.3–1.5)< 0.001*
Nonhematological657500.031.3 (1.2–1.4)< 0.001*
Mouth2410.462.3 (1.5–3.4)< 0.001*
Nasopharynx115.951.8 (0.9–3.3)0.08
Esophagus84.591.7 (0.8–3.4)0.19
Stomach2324.910.9 (0.6–1.4)0.80
Colorectal4877.480.6 (0.5–0.8)< 0.001*
Liver9455.861.7 (1.4–2.1)< 0.001*
Gall bladder77.440.9 (0.4–1.9)0.93
Pancreas109.891.0 (0.5–1.9)1.00
Lung9058.191.5 (1.2–1.9)< 0.001*
Skin1810.771.7 (1.0–2.6)0.05
Breast12492.471.3 (1.1–1.6)0.002*
Uterus3242.550.8 (0.5–1.1)0.11
Ovary2011.151.8 (1.1–2.8)0.02*
Prostate2011.601.7 (1.1–2.7)0.03*
Bladder2014.291.4 (0.9–2.2)0.18
Kidney1914.701.3 (0.8–2.0)0.32
Brain74.731.5 (0.6–3.0)0.40
Thyroid gland4214.412.9 (2.1–3.9)< 0.001*
Hematological8421.493.9 (3.1–4.8)< 0.001*
NHL5111.114.6 (3.4–6.0)< 0.001*
Multiple myeloma133.094.2 (2.2–7.2)< 0.001*
Leukemia206.922.9 (1.8–4.5)< 0.001*
  • * p < 0.05. NHL: non-Hodgkin lymphoma; SIR: standardized incidence ratio.